Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NewcelX Ltd. (NCEL)
USD3.93
-0.05 (-1.26%)
CH NASDAQ Healthcare Biotechnology
Address
The Circle 6 8058
Zurich, CH
Zurich, CH
CEO
Ronen Twito
Website
newcelx.com
IPO
2025-10-24
CIK 1783036 ISIN CH1442297896
Also trades on
NASDAQ Capital Market · NCEL (USD)
NASDAQ Capital Market · NLSP (USD)
NASDAQ Capital Market · NLSPW (USD)
Description
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.93
-0.05 (-1.26%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
52.4K
Beta
0.92
Float Shares
450.0K
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.56% | +6.67% | -20.18% | +21.38% | -12.22% | +85.26% | -84.07% | -99.17% | -99.74% | -99.70% | -99.70% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
3.93
DCF (Unlevered)
10.10
+157.1%
DCF (Levered)
10.79
+174.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-30.40
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+91.8% ★ Q4'25: +192.1% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-42.4% Q4'25: -74.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+2,390.8% Q4'25: +3.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q4'25: -0.09× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
—
|
—
|
132.52M
132.52M – 132.52M
|
178.62M
178.62M – 178.62M
+34.8% YoY
|
| EBITDA |
-3.63M
|
-2.24M
|
—
— – —
|
—
— – —
|
| EBIT |
-3.64M
|
-2.29M
|
—
— – —
|
—
— – —
|
| Net Income |
-1.98M
est: -2.47M (+19.8%)
|
-8.30M
est: -27.78M (+70.1%)
|
69.76M
69.76M – 69.76M
+351.1% YoY
|
106.18M
106.18M – 106.18M
+52.2% YoY
|
| SGA |
3.21M
|
1.35M
|
—
— – —
|
—
— – —
|
| EPS |
-26.30
est: -16.00 (-64.4%)
|
-2.16
est: -180.00 (+98.8%)
|
452.00
452.00 – 452.00
+351.1% YoY
|
688.00
688.00 – 688.00
+52.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
4
Total invested
1.8K
Insider transactions (90d)
2
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
4
+3 vs prev Q
New positions
3
Closed positions
0
Increased
3
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | UBS GROUP AG | 684.00 +684.0 (+100.0%) | 1.5K +1.5K (+100.0%) | 0.17% +0.171 pp | 0.00% +0.000 pp | USD2.12 +0.0% | 1 qtrs NEW |
| 2 | TOWER RESEARCH CAPITAL LLC (TRC) | 147.00 +147.0 (+100.0%) | 312.00 +312.0 (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD2.12 +0.0% | 1 qtrs NEW |
| 3 | CORECAP ADVISORS, LLC | 3.00 +— (+0.0%) | 6.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.67 +26.9% | 2 qtrs — |
| 4 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 1.00 +1.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 +6.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
327.3K
Shares disposed
—
Cash buys
4.00
Cash sales
—
Net activity
+327,271
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | Samuel Olivier | Director | P-Purchase | A | Common Shares, par value CHF 0.05 per share | 81,818 | 2.75 | 225.0K | 81,818 | D | ↗ |
| 2026-04-27 | Revel Michel | Director / Officer / 10% Owner | P-Purchase | A | Warrant (right to buy) | 76,363 | 3.03 | 231.0K | 76,363 | D | ↗ |
| 2026-03-18 | Zwyer Alexander | Director | — | — | Option to Purchase Ordinary Shares | 50,143 | 7.62 | 382.1K | 0 | D | ↗ |
| 2026-03-18 | Twito Ronen | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 272,399 | D | ↗ |
| 2026-03-18 | Samuel Olivier | Director | — | — | Option to Purchase Ordinary Shares | 13,676 | 7.62 | 104.2K | 0 | D | ↗ |
| 2026-03-18 | Revel Michel | Director / Officer | — | — | Option to Purchase Ordinary Shares | 9,117 | 7.62 | 69.5K | 0 | D | ↗ |
| 2026-03-18 | Oren Liora | Director | — | — | Option to Purchase Ordinary Shares | 9,117 | 7.62 | 69.5K | 0 | D | ↗ |
| 2026-03-18 | Hagai Omri | Officer | — | — | Option to Purchase Ordinary Shares | 11,396 | 7.62 | 86.8K | 0 | D | ↗ |
| 2026-03-18 | Galili Tamar | Director | — | — | Option to Purchase Ordinary Shares | 9,117 | 7.62 | 69.5K | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
450.0K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yossi Ben-Yossef | Honorary President & Strategic Consultant | 1M | male |
| Alexander Zwyer | Chief Business Officer & Executive Director | 557.0K | male |
| Ronen Twito | Chief Executive Officer & Executive Chairman | 356.0K | male |
| Eric Konofal | Head of Doxa Program | 122.0K | male |
| Omri Hagai | Chief Financial Officer | 14.0K | male |
| Michel Revel | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director | 4.0K | — |
| Ariel Revel | Director of Medical Affairs | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NCEL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
